St. Mary’s Medical Center is the First Hospital in Florida to Treat Stroke Patients with Novel TIGERTRIEVERÔ Stroke Device

St. Mary’s Medical Center is the first hospital in Florida to remove a blood clot in the brain using Rapid Medical’s new TIGERTRIEVER device—the only clot removal tool that is adjustable inside the brain. TIGERTRIEVER enables neuro interventionalists to better remove blood clots and restore blood flow to the brain following a stroke—a condition that devastates 800,000 Americans annually. Dr. Ali Malek, medical director of the comprehensive stroke center at the hospital, performed the procedure.

“This new technology gives our team an even better opportunity to capture clots that form in the brain so we can treat someone having a stroke as quickly as possible,” said Dr. Ali Malek. “Using the TIGERTRIEVER is a breakthrough in our community, and we look forward to providing the level of care needed for patients who come to our comprehensive stroke center.”

TIGERTRIEVER is the first and only adjustable clot retriever, providing physicians with greater control and adaptability to varying patient anatomy and circumstances. While viewing the device under x-ray guidance, physicians can adjust it to match the vessel size and better capture the clot.

“This is just another example as to why St. Mary’s Medical Center continues to be at the forefront of neurologic care when it comes to treating strokes,” said Cynthia McCauley, chief executive officer of St. Mary’s Medical Center & Palm Beach Children’s Hospital. “We look forward to using this new technology to treat our patients so they can receive the quality care they deserve when they are brought to our hospital.”

St. Mary’s Medical Center is an award-winning Comprehensive Stroke Center providing quality care in stroke prevention, stroke management, and stroke rehabilitation. Our center is equipped with some of the latest diagnostic and therapeutic advances to quickly and accurately diagnose and treat stroke patients. Patients benefit from a range of comprehensive medical, surgical and minimally invasive treatment options, as well as access to clinical trials and research.

For more information on our comprehensive services, go to www.stmarysmc.com or call 561-844-6300.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version